New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
Scribe Therapeutics Inc. (SCTX) P/E ratio
Scribe Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | n/m |
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| EIKN Eikon Therapeutics, Inc. compare | n/m |
| SABS SAB Biotherapeutics, Inc. compare | n/m |
| SCTX Scribe Therapeutics Inc. | n/m |
| QTTB Q32 Bio Inc. compare | 2.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 21.7× |
| Market median | 16.6× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)